Malaria drug's warnings strengthened by FDA

The FDA updated on Monday the warning on the antimalarial treatment mefloquine hydrochloride, which is sold under brand names such as Mefliam, Mephaquin and Lariam. The drug's label must bear the black box warning because the treatment could cause psychiatric adverse events including depression, paranoia, confusion and anxiety, as well as neurologic side effects including tinnitus, loss of balance and dizziness, the agency said. "FDA has revised the patient Medication Guide dispensed with each prescription and wallet card to include this information and the possibility that the neurologic side effects may persist or become permanent," the agency said in a statement.

View Full Article in:

New York Times (tiered subscription model), The · NBC News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC